文献速递膀胱癌与上尿路尿路上皮癌

多基因尿液生物标志物检测在多中心研究中监测复发性尿路上皮癌的性能特征

Performance Characteristics of a Multigene Urine Biomarker Test for Monitoring for Recurrent Urothelial Carcinoma in a Multicenter Study.
PubMed 文献 · J Urol · 2016-12-14

本研究前瞻性收集763例接受膀胱复发性尿路上皮癌常规监测患者的1036份尿样,开发并验证Cxbladder Monitor检测。该检测结合基因表达与临床患者数据,内部验证灵敏度0.93、阴性预测值0.97、检测阴性率0.34,高危进展复发疾病灵敏度0.95,低级别Ta期疾病灵敏度0.86,假阴性结果在所有样本中少于1.5%。

要点

  • Cxbladder Monitor内部验证灵敏度0.93,阴性预测值0.97,检测阴性率0.34。
  • 高危进展复发疾病灵敏度0.95,低级别Ta期疾病灵敏度0.86。
  • 假阴性结果在所有收集样本中少于1.5%。

核心结论

  • Cxbladder Monitor检测结合高灵敏度和高阴性预测值以排除尿路上皮癌,可作为膀胱镜检查的确认性阴性辅助手段,可能为推迟或避免膀胱镜监测复发提供依据。

研究设计与样本

  • 前瞻性收集763例接受膀胱复发性尿路上皮癌常规监测患者的1036份尿样,用于开发和验证Cxbladder Monitor检测,该检测结合基因表达、临床和患者数据。

主要发现

  • Cxbladder Monitor内部验证灵敏度为0.93,阴性预测值为0.97,检测阴性率为0.34。
  • 高危进展复发疾病(所有高级别疾病及低级别、分期T1或以上疾病)灵敏度为0.95,低级别Ta期疾病灵敏度为0.86。
  • 亚组分析表明诊断性能在不同年龄组、性别或肿瘤分期之间无显著差异。
  • 灵敏度不受过去6个月内辅助卡介苗(bacillus Calmette-Guérin)治疗影响。
  • 假阴性结果在所有收集样本中少于1.5%。

临床怎么用

  • 作者认为该检测可作为膀胱镜检查的确认性阴性辅助手段,可能为推迟或避免膀胱镜监测复发提供依据。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Urothelial carcinoma is associated with a high rate of recurrence. Guidelines recommend rigorous, regular surveillance programs that are invasive and expensive. This study describes a noninvasive urine test with sufficient sensitivity to rule out recurrent urothelial carcinoma, thereby reducing invasive diagnostic evaluations without compromising patient care. METHODS AND MATERIALS: A total of 1,036 urine samples were prospectively collected from 763 patients undergoing routine surveillance for recurrent urothelial carcinoma of the bladder. The purpose was to develop and validate a test with combined high sensitivity and high negative predictive value. Cxbladder Monitor combines gene expression, clinical and patient data, and it is designed to rule out the presence of recurrent urothelial carcinoma. RESULTS: Cxbladder Monitor showed an internally validated sensitivity of 0.93 with a negative predictive value of 0.97 and a test negative rate of 0.34. Sensitivity was 0.95 for recurrent disease with a high risk of progression (all high grade disease and low grade, stage T1 or greater disease) compared with 0.86 for low grade Ta disease. Subgroup analyses indicated that diagnostic performance was not significantly different in different age groups, or by gender or tumor stage. Sensitivity was not affected by adjuvant bacillus Calmette-Guérin treatment within the last 6 months. False-negative findings were reported in fewer than 1.5% of all samples collected. CONCLUSIONS: The Cxbladder Monitor test offers combined high sensitivity and high negative predictive value to rule out urothelial carcinoma. This test has clinical utility as a confirmatory negative adjunct to cystoscopy, potentially justifying the postponement/avoidance of cystoscopic investigations to monitor recurrence in patients.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Kavalieris L, O'Sullivan P, Frampton C, et al. Performance Characteristics of a Multigene Urine Biomarker Test for Monitoring for Recurrent Urothelial Carcinoma in a Multicenter Study. J Urol. 2016. PMID: 27986532. doi:10.1016/j.juro.2016.12.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。